Hepatocyte growth factor · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Hepatocyte growth factor shows late clinical disease relevance led by gastric cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P14210. Start with gastric cancer, then reuse UniProt P14210 as the stable protein anchor across project notes and exports.
Start with gastric cancer, then reuse UniProt P14210 as the stable protein anchor across project notes and exports.
Hepatocyte growth factor shows late clinical disease relevance led by gastric cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with gastric cancer because it currently carries late clinical support. Linked drugs include RILOTUMUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyHepatocyte growth factor
Review this target as Hepatocyte growth factor, mapped to UniProt P14210. Sequence length is 728 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Hepatocyte growth factor as ChEMBL target CHEMBL5479, mapped to UniProt P14210. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Hepatocyte growth factor is the right protein anchor across sources, using UniProt P14210 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why gastric cancer is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Hepatocyte growth factor |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P14210 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Hepatocyte growth factor |
| UniProt Accession | P14210 |
| Component Type | Protein |
| Sequence Length | 728 aa |
Hepatocyte growth factor
Review this target as Hepatocyte growth factor, mapped to UniProt P14210. Sequence length is 728 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Hepatocyte growth factor shows late clinical disease relevance led by gastric cancer. 5 more disease programs remain visible in the same review block.
Start review with gastric cancer because it currently carries late clinical support. Linked drugs include RILOTUMUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL447602 | 7.23 | IC50 | 59.0 | Preclinical |
| CHEMBL453737 | 7.19 | IC50 | 64.0 | Preclinical |
| CHEMBL444560 | 6.79 | IC50 | 161.0 | Preclinical |
| CHEMBL461648 | 6.5 | IC50 | 313.0 | Preclinical |
| CHEMBL2337901 | 5.71 | Kd | 1950.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 3 | 4 | 6.9 |
| single protein format | 1 | 1 | 5.7 |